Aphelion Capital

Aphelion Capital is one of the cleaner expressions of a thesis that has become unfashionable to articulate but never stopped working: build medical devices and digital health tools that improve outcomes while keeping per-patient costs flat or lower. Out of Mill Valley, the firm has put together a portfolio that quietly tracks the most durable themes in twenty-first century medtech. Insulet, the Omnipod insulin pump maker, anchors the track record with a public-market exit. Bardy Diagnostics built a long-wear cardiac monitor patch and was acquired by Hill-Rom. Phagenesis is reshaping post-stroke dysphagia management. Biolinq is developing intradermal continuous glucose biosensors. Laplace Interventional and Nectero Medical pursue structural heart and vascular indications, while ExplORer Surgical built procedural workflow software for the OR. The collective signal: Aphelion underwrites incremental, capital-efficient innovation in spaces where reimbursement codes already exist or are within reach.

The firm’s stated thesis is rigorous about economics. Aphelion backs early- and mid-stage medical device and digital health companies whose products improve patient outcomes while keeping per-patient costs flat or lower. In practice, this filter screens out most blue-sky platform plays and most consumer wellness companies. The implied target is a team of two to ten people building a Class II or III device, a cardiac or vascular interventional product, or a tightly-scoped digital health workflow tool, with a credible reimbursement pathway and a clinical advisor bench that can defend the value proposition to payers and IDNs. Therapeutic area is open: cardiology, neurology, GI, oncology, surgical workflow, and metabolic disease all appear in the disclosed portfolio. The constant is capital efficiency. Aphelion writes early-stage checks expecting that the company can reach a value-creating clinical or commercial milestone without requiring a long, expensive platform expansion.

The disclosed portfolio breaks roughly into three buckets. Cardiac and vascular is the largest, with Insulet adjacent at the cardiometabolic edge and Bardy, Laplace Interventional, and Nectero Medical sitting squarely inside structural heart and aortic disease. Neuro and GI form a second cluster around Phagenesis and Biolinq’s metabolic biosensor work. Surgical workflow software via ExplORer Surgical hints at the firm’s openness to digital tools when those tools sit inside an existing procedural revenue stream rather than trying to create a new one. What does not appear: pure consumer health apps, telehealth platforms without clinical workflow embedding, or generalist SaaS plays. Founders should read this portfolio as a clear declaration that Aphelion wants devices and clinically-anchored software, not D2C wellness.

Check size is listed at $1M to $5M, which positions Aphelion as a meaningful seed and Series A participant rather than a growth lead. The firm leads and co-leads early rounds and follows aggressively in subsequent rounds when the data supports it. A common pattern in the disclosed portfolio is Aphelion as a lead or major co-investor at seed or Series A, syndicated alongside specialist medtech firms and strategics. The firm also runs Cardeation Capital alongside the American Heart Association, UPMC, and Philips, a cardiovascular-focused vehicle that gives Aphelion an unusual on-ramp to clinical and corporate validation in the cardiac space. Founders building in cardiology should expect that the Cardeation relationship factors into both diligence and post-investment support.

The partnership is small and operationally hands-on. Founder and Managing Partner Ned Scheetz leads the practice. Chris Baker, MD serves as Clinical Partner, bringing physician-level diligence to most device deals. Jake Martellaro covers principal-level sourcing and deal execution. The lean team means founders are likely to interact directly with one of the three throughout the process, with Scheetz typically owning final investment decisions. Pitches should be calibrated for a partnership that will dig deeply into clinical data, reimbursement strategy, and unit economics rather than market sizing slides.

Warm intros from co-investors in cardiology and structural heart, from senior figures at the American Heart Association ecosystem, or from physician-founders inside the existing portfolio carry the most weight. Aphelion is not a high-volume content firm; the team rarely appears on podcasts or speaks at major conferences in marquee slots. Public communication is sparse. Founders should compensate by leaning on warm relationships rather than cold inbound and by arriving with reimbursement, clinical, and commercial diligence already done.

Approach Aphelion when the company has a defined clinical indication, a credible regulatory path, and a thesis on payer adoption. Avoid Aphelion if the pitch is a platform story, a consumer wellness brand, or a digital health tool without a clinical workflow anchor. The firm has built its reputation on disciplined underwriting and on backing teams that ship products through FDA and into commercial use without burning a hundred million dollars. Founders who want a patient lead investor with deep medtech instincts will find a strong fit; founders looking for a momentum-driven valuation lift will find the diligence frustratingly thorough.